QPPV.COM KNOWLEDGE ASSESSMENT

Emicizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Test your understanding of the concepts covered by Emicizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 Why does inhibitor status need to be captured explicitly in an emicizumab case?

It determines whether emicizumab can bind FX. It affects the interpretation of treatment history and the selection and risks of rescue haemostatic therapy. It determines whether subcutaneous administration is technically possible. It is relevant only to product quality complaints.

Question 2 of 10 A report states that a patient had 'high FVIII' while receiving emicizumab. What is the first professional interpretation?

The result proves excessive endogenous FVIII production. The result may be assay-related and requires identification of the methodology before biological interpretation. The result confirms that emicizumab has been neutralised. The result is necessarily evidence of thrombosis.

Question 3 of 10 Why should aggregate analyses generally distinguish patients with FVIII inhibitors from those without inhibitors?

Emicizumab has a different molecular target in each population. The populations differ materially in rescue-treatment options and associated haemostatic risks, especially regarding bypassing agents. Patients without inhibitors cannot experience breakthrough bleeding. Regulatory analysis must always exclude patients with inhibitors.

Question 4 of 10 During perioperative review of a patient receiving emicizumab, which question is most important for understanding treatment-related risk?

Was the patient's aPTT within the reference range at any time? What procedure occurred, what was its bleeding risk, which haemostatic agents were given, and what assays guided decisions? Did the patient previously receive any unrelated monoclonal antibody? Was the emicizumab injection site free of erythema?

Question 5 of 10 Which set of data is most useful when evaluating a suspected emicizumab medication error followed by bleeding?

Only the name of the person who administered the injection Prescribed and actual dose, vial strength, volume, body weight, schedule, administrator and clinical consequence Only the patient's baseline FVIII inhibitor titre Only the batch number and injection-site appearance

Question 6 of 10 Which statement best distinguishes thrombotic microangiopathy from a nonspecific report of thrombosis in an emicizumab case?

TMA is defined solely by a shortened aPTT. TMA assessment requires evaluation of findings such as thrombocytopenia, haemolysis and renal involvement, not merely an occluded vessel. TMA is another term for every macrovascular thrombotic event. TMA can be diagnosed from the emicizumab dose without clinical or laboratory information.

Question 7 of 10 Which follow-up is most appropriate for an unexpected coagulation laboratory result in a patient receiving emicizumab?

Repeat the same test without documenting its method. Obtain the exact assay, reagent or platform, timing relative to emicizumab and FVIII exposure, and the clinical purpose of testing. Assume that every abnormal result represents a pharmacological adverse reaction. Discard the result because laboratory data are never relevant to pharmacovigilance.

Question 8 of 10 Which statement best describes the relevance of aPCC exposure in a patient receiving emicizumab?

aPCC exposure is irrelevant because emicizumab replaces all haemostatic therapy. High cumulative aPCC exposure can add excessive procoagulant activity and is important when assessing thrombosis or TMA. aPCC is used only to diagnose laboratory interference. aPCC prevents all thrombotic complications associated with emicizumab.

Question 9 of 10 How should a bleeding event that follows an incorrect emicizumab dose generally be represented in pharmacovigilance case assessment?

Record only the bleeding because the dosing error is not clinically relevant. Record only the medication error because adverse outcomes should not be linked to errors. Record the medication error and the clinical consequence separately, with an appropriate medical link. Record the event only as an assay interference.

Question 10 of 10 A patient who was initially well controlled on emicizumab develops recurrent unexpected bleeding. Which assessment is most appropriate?

Code the case immediately as disease progression and close follow-up. Investigate adherence, dose and administration accuracy, body weight, anti-drug antibodies and alternative explanations. Assume that FVIII inhibitors have neutralised emicizumab. Interpret a normal aPTT as confirmation that the bleeding is unrelated to treatment.

Emicizumab: Classification, History, Mechanism of Action, Safety and Pharmacovigilance

Cookie Settings